As Silicon Valley pours unprecedented sums into artificial intelligence, the enduring cultural footprint of Theranos founder Elizabeth Holmes continues to captivate observers, raising urgent questions about founder worship and corporate oversight. She was still a teenager when she founded Theranos, touting technology capable of performing medical tests using only a few drops of blood.
Medical oncologist David Agus recalls his first encounter with Holmes in a green room at a health conference as an immediate shock. While personable and pleasant off-stage, Holmes underwent a startling transformation once she stepped in front of an audience. “The accent changed: this deep voice, very serious,” Agus recalls. “It was as if I had met a person and then interviewed a separate person. That transition from the green room to the stage – I had never experienced something like that before.”
The Illusion of the Female Steve Jobs
By 2014, Theranos claimed a valuation of $9bn, and Holmes was crowned America’s youngest self-made female billionaire with a net worth of $4.5bn.
University of Washington history professor Margaret O’Mara points out that Holmes capitalized on a distinct cultural moment when tech investors hungered for tangible, world-changing innovation rather than mere consumer applications. “She stands out in her ascent as a female entrepreneur at a time when men were dominating the scene and she was doing something that was in tech but seemed to be change-the-world-tech,” O’Mara observes.
To me, that was the initial red flag,” Agus explains. Stanford University professor John Ioannidis similarly published a 2015 commentary in the Journal of the American Medical Association highlighting the conspicuous absence of peer-reviewed data supporting Theranos’s technology.
From Boardrooms to Federal Prison
The house of cards collapsed following investigative reporting by the Wall Street Journal, driven in part by whistleblower concerns raised by Tyler Shultz, the grandson of Theranos board member George Shultz. Holmes resigned as chief executive in 2018, and the company dissolved shortly afterward. Following a federal trial, Holmes was sentenced in 2022 to more than 11 years in prison for wire fraud and conspiracy.
Before reporting to federal prison camp Bryan in Texas in May 2023, Holmes participated in the documentary You Can See Everything, directed by Nathan Fielder and Lance Oppenheim, which captured her domestic life with partner Billy Evans and their two children during her final 34 days of freedom. Off-camera developments revealed that Holmes and Evans continued planning new entrepreneurial ventures even as her imprisonment loomed. In 2025, two years into her prison sentence, Evans sought $18.5m in funding for Haemanthus, a startup holding patents for a device designed to scan blood, urine, and saliva samples using lasers.
The Broader Silicon Valley Reckoning
Reflecting on the psychological and financial dimensions of the scandal, O’Mara argues that the Theranos saga serves as an enduring warning about uncritical faith in charismatic leadership. The founder culture that propelled Holmes to unprecedented heights remains deeply entrenched in the technology sector, where wealth and power are concentrated among a small circle of individuals to a degree rarely seen since America’s Gilded Age.
As regulatory scrutiny adapts to modern technology booms, legal and financial experts continue to assess the institutional safeguards needed to prevent similar confidence tricks. Observers note that accountability in the healthcare and biotech sectors must remain rigorously data-driven, ensuring that compelling personal narratives never override peer-reviewed scientific validation.
